Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Vigil Neuroscience, Inc. (VIGL)

Sector - Healthcare

Price chart

N/A
Return from IPO

Company News

IPO Profile

About company

They are a microglia-focused company dedicated to improving the lives of patients, caregivers and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. Leveraging recent research implicating microglial dysfunction in neurodegenerative diseases, they utilize a precision medicine approach to develop a pipeline of therapeutic candidates, initially addressing genetically defined patient subpopulations, that they believe will activate and restore microglial function. Their lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). In November 2021, the FDA cleared their Investigational New Drug application (IND) for VGL101 in ALSP at doses up to 20 mg/kg. They initiated their first-in-human Phase 1 clinical trial with VGL101 in healthy volunteers in December 2021 and expect to announce topline data in the second half of 2022.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
34 2020

Contacts

Address: 1 Broadway, 7th Floor, Suite 07-300 Cambridge, Ma 02142

Telephone: (857) 254-4445

Web page: http://www.vigilneuro.com

IPO information

First Trade Date 1/7/2022
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 7
Shares Revised (MM) 7
Expected offer amount (MM) $112
Realized offer amount(MM) $98

Financial Data (last reporting year)

Market Cap (MM) $340.16
Revenues (MM) $0
Net Income (Loss) (MM) $-34.5

Voting

What do you think will happen with the VIGL share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Morgan Stanley

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Morgan Stanley/ Jefferies/ Stifel/ Guggenheim Securities
CO-Managers

Sector: Healthcare

Tweets about $VIGL

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats